Clinical trials: RCC, Renal Cell Cancer
Renal Cell Carcinoma
DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma
The aim of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells (DC) vaccine combined with cytokine-induced killer (CIK) cells in patients with renal cell carcinoma.
- Trial name
- NCT01924156
- Testing
- adenovirus-transfected DC + CIK
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Clear Cell RCC
A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma
This is an open label, single-centre phase 1/2 study involving a single dose of Temferon, an investigational Advanced Therapy Medicinal Product (ATMP), to treat patients with metastatic clear cell renal cell carcinoma (RCC) with…
- Trial name
- TEM-GU (NCT06716853)
- Testing
- Temferon, Pembrolizumab, Cabozantinib
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Genenta Science
Renal Cancer
Zero-ischemia Robot-assisted Partial Nephrectomy Using Near-infrared Fluorescence
Patients with renal cancer are commonly treated by robot-assisted partial nephrectomy. Renal artery clamping is commonly required inducing kidney ischemia during surgery. It impacts parenchymal and renal function.
- Trial name
- EMERALD (NCT03679572)
- Testing
- Robot assisted partial nephrectomy super-selective clamping, Robot assisted partial nephrectomy with renal artery clamping
- Where
- France
- Volunteers
- 31 people
- Sponsor
- University Hospital, Grenoble
Kidney Tumor, Renal Benign Neoplasm
Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors
The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about…
- Conditions
- Kidney Tumor, Renal Benign Neoplasm, Renal Malignant Tumor
- Trial name
- BIOPSy (NCT05728957)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Loyola University
Renal Cell Carcinoma, Quality of Life
Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours
The present study is an observational study designed to assess and compare clinical outcome and quality of life after nephron sparing treatment of small renal tumors.
- Trial name
- NCT04040530
- Testing
- CT-guided cryoablation, Partial nephrectomy
- Where
- 2 sites in Denmark
- Volunteers
- 187 people
- Sponsor
- Region of Southern Denmark
Metastatic Clear Cell Renal Cell Carcinoma
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
To determine the efficacy of multiple doses Lutetium-177-DOTA-girentuximab in patients with advanced clear cell renal cell carcinoma using RECIST criteria.
- Trial name
- NCT02002312
- Testing
- Lu-177-DOTA-girentuximab
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Radboud University Medical Center
Oncology, Solid Tumor
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma).
- Conditions
- Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03637803
- Testing
- MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
- Where
- 5 sites in United States
- Volunteers
- 63 people
- Sponsor
- 4D pharma plc
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Advanced Renal Cell Carcinoma (aRCC)
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab +…
- Trial name
- NCT06345183
- Testing
- Nivolumab + Ipilimumab combination therapy, Pembrolizumab + Lenvatinib combination therapy
- Where
- United States
- Volunteers
- 327 people
- Sponsor
- Bristol-Myers Squibb
Von Hippel-Lindau Disease, Hemangioblastoma
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Von Hippel Lindau disease (VHLD) is an inherited syndrome characterized by vascular malformations, kidney cancer, adrenal gland and pancreas tumors.
- Conditions
- Von Hippel-Lindau Disease, Hemangioblastoma, Renal Cell Carcinoma, Pheochromocytoma
- Trial name
- VHLimage (NCT00970970)
- Testing
- 89Zr bevacizumab PET scan
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- University Medical Center Groningen
Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well tivantinib with or without erlotinib hydrochloride works in treating patients with metastatic or locally advanced kidney cancer that cannot be removed by surgery.
- Conditions
- Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma
- Trial name
- NCT01688973
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Tivantinib
- Where
- 214 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Solid Tumor
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in…
- Conditions
- Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT04787042
- Testing
- ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 316 people
- Sponsor
- Simcha IL-18, Inc.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 747 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Renal Cell Carcinoma
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
This is a single-arm, multicenter, phase 2 study of lenvatinib in combination with pembrolizumab (lenvatinib 20 mg/day + pembrolizumab 200mg q3weeks) in subjects with unresectable advanced or metastatic non-clear cell renal…
- Trial name
- NCT04267120
- Testing
- Lenvatinib, Pembrolizumab, Research blood collection
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Kidney Neoplasm, Kidney Stone
A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members
Approximately 30,000 new patients are introduced into dialysis and about 20,000 of them die every year in Japan. At present, about 300,000 patients are on dialysis and more than 10,000 patients are registered with the Japan Organ…
- Conditions
- Kidney Neoplasm, Kidney Stone, Ureteral Tumor, Ureteral Stricture
- Trial name
- NCT00994188
- Testing
- Restored Kidney Transplant Between Family Members
- Where
- 2 sites in Japan
- Volunteers
- 5 people
- Sponsor
- Tokushukai Medical Group
Renal Cell Carcinoma
Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma
30% of renal cell carcinoma patients have metastases, mostly in lung, liver and bones at the time of diagnosis. Because of poor response to radiation therapy or chemotherapy, several studies have been initiated to find…
- Trial name
- NCT01240005
- Testing
- DCIK
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qingdao University
Prostate Cancer, Bladder Cancer
Decipher Genomics Resource for Intelligent Discovery
To prospectively evaluate the utility of genomic expression data and whole slide digital pathology image data as a tool to better characterize the tumors of individual patients, and to understand how genomic and histologic…
- Conditions
- Prostate Cancer, Bladder Cancer, Renal Cancer
- Trial name
- GRID® (NCT02609269)
- Testing
- Decipher Cancer Classifier
- Volunteers
- 1,000,000 people
- Sponsor
- GenomeDx Biosciences Corp
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Neoplasms, Renal Cell Carcinoma
Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland
Patient receiving sunitinib according the clinician's independent decision as first-line treatment of advanced renal cell carcinoma (RCC) will be asked for informed consent.
- Trial name
- NCT00980213
- Testing
- sunitinib
- Where
- 5 sites in Finland
- Volunteers
- 80 people
- Sponsor
- Pirkko-Liisa Kellokumpu-Lehtinen
Renal Cell Carcinoma
Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
The NESCIO-trial is a multicenter, randomized, open-label, three-arm phase II trial investigating different combinations of neoadjuvant immunotherapy in patients with primary, resectable, intermediate to high-risk, clear-cell…
- Trial name
- NESCIO (NCT05148546)
- Testing
- Neoadjuvant nivolumab, Neoadjuvant ipilimumab, Neoadjuvant relatlimab
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 69 people
- Sponsor
- The Netherlands Cancer Institute